Evaluation of FloSeal as a potential intracavitary hemostatic agent
- PMID: 16508500
- DOI: 10.1097/01.ta.0000204440.48338.79
Evaluation of FloSeal as a potential intracavitary hemostatic agent
Abstract
Background: Noncompressible hemorrhage is a major cause of death in combat and civilian trauma. When surgery is unavailable, one potential solution to such hemorrhage might be the introduction of an agent into the closed body cavity to provide hemostasis via a combination of coagulative and tamponade effects. FloSeal is an agent containing collagen and thrombin with proven hemostatic efficacy when applied with manual pressure to a bleeding site. The current studies were conducted to analyze the ability of FloSeal to reduce blood loss and increase survival time when applied directly, immediately, and without additional pressure to a severe liver injury in rats.
Methods: Male rats were anesthetized and catheters were placed in the carotid artery (for measurement of blood pressure) and jugular vein (for resuscitation with lactated Ringers, 3.3 mL/min/kg BW). After midventral laparotomy, the liver was exposed and caudal portions of both medial lobes ( approximately 1% of body weight) were rapidly excised. FloSeal (5 mL, 800 units Thrombin/mL) or vehicle (5 mL, 0.9% NaCl) was directly and immediately applied to the cut liver surface. The abdominal cavity was closed and resuscitation initiated. After hemorrhage-induced death, or after euthanasia at 90 minutes, fluid loss (blood + resuscitation fluid) was measured.
Results: Compared with the control group, direct and immediate application of FloSeal was associated with a reduction in the amounts of fluid lost into the abdominal cavity (p < 0.01) (19.2 +/- 1.5 versus 25.1 +/- 1.5 g) and enhanced mean arterial pressure at 5, 20, and 30 minutes after injury (p = 0.02), but neither survival time (p = 0.12) nor percent survival (p = 0.17) differed between treated and control groups.
Conclusions: Reductions in fluid loss after liver injury and hemorrhage in FloSeal-treated rats in the absence of additional applied pressure are encouraging, and provide evidence for the ability of FloSeal to reduce blood loss when applied immediately and directly to a bleeding tissue.
Similar articles
-
Comparison of a new hemostatic agent to current combat hemostatic agents in a Swine model of lethal extremity arterial hemorrhage.J Trauma. 2007 Aug;63(2):276-83; discussion 283-4. doi: 10.1097/TA.0b013e3180eea8a5. J Trauma. 2007. PMID: 17693824
-
Modified rapid deployment hemostat bandage reduces blood loss and mortality in coagulopathic pigs with severe liver injury.J Trauma. 2003 Aug;55(2):275-80; discussion 280-1. doi: 10.1097/01.TA.0000079375.69610.89. J Trauma. 2003. PMID: 12913637
-
Comparative efficacy of granular and bagged formulations of the hemostatic agent QuikClot.J Trauma. 2007 Oct;63(4):775-82. doi: 10.1097/TA.0b013e31805f7023. J Trauma. 2007. PMID: 18090005
-
Use of FloSeal hemostatic sealant in transsphenoidal pituitary surgery: technical note.Neurosurgery. 2002 Aug;51(2):513-5; discussion 515-6. Neurosurgery. 2002. PMID: 12182794 Review.
-
Current concepts in fluid resuscitation for prehospital care of combat casualties.US Army Med Dep J. 2011 Apr-Jun:18-24. US Army Med Dep J. 2011. PMID: 21607903 Review.
Cited by
-
A hydrogel sealant for the treatment of severe hepatic and aortic trauma with a dissolution feature for post-emergent care.Mater Horiz. 2017 Mar 1;4(2):222-227. doi: 10.1039/C6MH00378H. Epub 2016 Dec 23. Mater Horiz. 2017. PMID: 28868146 Free PMC article. No abstract available.
-
The effectiveness of FloSeal matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study.Langenbecks Arch Surg. 2009 Sep;394(5):837-42. doi: 10.1007/s00423-009-0497-5. Epub 2009 May 7. Langenbecks Arch Surg. 2009. PMID: 19421770 Clinical Trial.
-
Efficacy of a topical bovine-derived thrombin solution as a hemostatic agent in a rodent model of hepatic injury.Can J Vet Res. 2015 Oct;79(4):303-8. Can J Vet Res. 2015. PMID: 26424911 Free PMC article.
-
Surgical control of life-threatening post-ERCP bleeding with a gelatin matrix-thrombin hemostatic agent.Int J Surg Case Rep. 2012;3(9):471-3. doi: 10.1016/j.ijscr.2012.05.014. Epub 2012 Jun 2. Int J Surg Case Rep. 2012. PMID: 22743012 Free PMC article.
-
Haemostatics in surgery and our experience in the enucleoresection of renal cell carcinoma.World J Surg Oncol. 2010 May 12;8:37. doi: 10.1186/1477-7819-8-37. World J Surg Oncol. 2010. PMID: 20462437 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical